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Background: Obesity and particularly the metabolic syndrome, which is often associated with obesity, combine a
major risk for type 2 diabetes and cardiovascular disease. Emerging evidence indicate obesity-associated subclinical
inflammation primarily originating from adipose tissue as a common cause for type 2 diabetes and cardiovascular
disease. However, a suitable and well-characterized mouse model to simultaneously study obesity-associated
metabolic disorders and atherosclerosis is not available yet. Here we established and characterized a murine
model combining diet-induced obesity and associated adipose tissue inflammation and metabolic deteriorations
as well as atherosclerosis, hence reflecting the human situation of cardio-metabolic disease.
Methods: We compared a common high-fat diet with 0.15% cholesterol (HFC), and a high-fat, high-sucrose diet
with 0.15% cholesterol (HFSC) fed to LDL receptor-deficient (LDLR−/−) mice. Insulin resistance, glucose tolerance,
atherosclerotic lesion formation, hepatic lipid accumulation, and inflammatory gene expression in adipose tissue
and liver were assessed.
Results: After 12–16 weeks, LDLR−/− mice fed HFSC or HFC developed significant diet-induced obesity, adipose
tissue inflammation, insulin resistance, and impaired glucose tolerance compared to lean controls. Notably, HFSC-fed
mice developed significantly higher adipose tissue inflammation in parallel with significantly elevated atherosclerotic
lesion area compared to those on HFC. Moreover, LDLR−/− mice on HFSC showed increased insulin resistance and
impaired glucose tolerance relative to those on HFC. After prolonged feeding (20 weeks), however, no significant
differences in inflammatory and metabolic parameters as well as atherosclerotic lesion formation were detectable
any more between LDLR−/− mice fed HFSC or HFC.
Conclusion: The use of high sucrose rather than more complex carbohydrates in high-fat diets significantly
accelerates development of obesity-driven metabolic complications and atherosclerotic plaque formation parallel
to obesity-induced adipose tissue inflammation in LDLR−/− mice. Hence LDLR−/− mice fed high-fat high-sucrose
cholesterol-enriched diet appear to be a suitable and time-saving animal model for cardio-metabolic disease.
Moreover our results support the suggested interrelation between adipose tissue inflammation and atherosclerotic
plaque formation.
Keywords: Metabolic syndrome, Diet-induced obesity, Sucrose-enrichment, Adipose tissue inflammation, Insulin
resistance, Glucose intolerance, Atherosclerosis, Type 2 diabetes, Cardio-metabolic disease* Correspondence: thomas.stulnig@meduniwien.ac.at
†Equal contributors
1Christian Doppler Laboratory for Cardio-Metabolic Immunotherapy and Clin-
ical Division of Endocrinology and Metabolism, Department of Medicine III,
Medical University of Vienna, Vienna, Austria
Full list of author information is available at the end of the article
© 2014 Neuhofer et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Neuhofer et al. Cardiovascular Diabetology 2014, 13:23 Page 2 of 12
http://www.cardiab.com/content/13/1/23Background
Obesity is strongly associated with the so-called metabolic
syndrome, which comprises a combination of factors con-
ferring risk for type 2 diabetes and cardiovascular disease
[1]. Hence in humans, risk for metabolic deterioration and
atherosclerosis often occurs in common and is based on
insulin resistance and inflammation [2,3]. Inflammation is
a common soil of insulin resistance and atherosclerosis
underlying type 2 diabetes and cardiovascular disease,
respectively. Especially obesity-induced chronic low grade
inflammation that primarily originates from the adipose
tissue has been shown to play a crucial role in the de-
velopment of obesity-related diseases [4,5]. In particular,
visceral adipose tissue and liver are the primary source
and target of circulating inflammatory mediators in
obesity-induced inflammation [6]. In both adipose tissue
and liver, macrophages, and other immune cells such
as T-cells are a main source of inflammatory cytokines
such as tumor necrosis factor-α (TNFα), interleukin-6
(IL-6), monocyte chemoattractant protein-1 (MCP-1),
and osteopontin [7-9] which drive the low-grade inflam-
mation by mechanisms which need to be elucidated in
more detail.
Recently, osteopontin has been identified as one of the
key molecules involved in the pathogenesis of atheroscler-
osis [10-13], as well as type 2 diabetes [14,15]. Moreover,
osteopontin plays a role in the pathogenesis of nonalcoholic
fatty liver disease (NAFLD) [16,17].
Epidemiological studies emphasize the relationship be-
tween sugar consumption e.g. by sugar-sweetened bever-
ages, long-term weight gain and type 2 diabetes mellitus
[18,19]. Furthermore, rapidly absorbable carbohydrates
such as sucrose leading to high dietary glycemic load
may increase type 2 diabetes and cardiovascular risk
independently of obesity by provoking inflammation
and insulin resistance [20-22]. In addition, fructose also
increases blood pressure, dyslipidemia and visceral adi-
posity [23,24].
In order to reflect the highly prevalent human situation
of cardio-metabolic risk and to elucidate mechanisms
by which metabolic complications associated with obesity
accelerate atherosclerosis in more detail, a well-character-
ized mouse model is necessary which combines obesity,
and insulin resistance with development of significant
atherosclerosis. Although a number of mouse strains
develop obesity and obesity-associated insulin resistance
under certain conditions [25,26] most of these models
are resistant to atherosclerosis [27]. On the other hand,
both LDL receptor-deficient (LDLR−/−) and particularly
apolipoprotein E-deficient (ApoE−/−) mice display marked
atherosclerosis [28,29] but ApoE−/− mice develop lower
diet-induced obesity, less profound insulin resistance
and adipose tissue inflammation when fed a high-fat
diet [30-32].Hence, LDLR−/− mice seem to be a valuable basis to
establish an atherosclerotic mouse model combined with
high-fat diet-induced obesity and insulin resistance. How-
ever, the impact of a high glycemic load has not been
compared to a common high-fat diet in this murine model.
In order to develop and standardize a mouse model reflect-
ing the human situation of metabolic syndrome with
diet-induced obesity, adipose tissue inflammation promot-
ing insulin resistance and atherosclerosis we investigated
the effect of a common high-fat diet and a sucrose-
enriched high-fat diet in LDLR−/− mice. In addition,
ApoE−/− mice were used as a positive control for ath-
erosclerotic plaque formation.
Here we demonstrate that feeding LDLR−/− mice a
high-fat, high-sucrose cholesterol-enriched diet for 16
weeks represents a suitable mouse model for human
cardio-metabolic disease. Moreover, our findings suggest
an interrelation between increased obesity-associated
inflammation and elevated atherosclerotic plaque for-
mation in LDLR−/− mice.
Methods
Animals and diet
Male LDLR−/− and ApoE−/− mice, both on a C57BL/6 J
background were purchased from Charles River Labora-
tories (Sulzfeld, Germany). At 9 weeks of age LDLR−/−
mice were placed on either a high-fat diet enriched with
0.15% cholesterol (HFC) containing 60 kcal% fat (pri-
marily lard) and 20 kcal% carbohydrates with 6.8 kcal%
deriving from sucrose (D01120401; Research Diets Inc.,
New Brunswick, NJ, USA), a sucrose-enriched high-fat
diet with 0.15% cholesterol (HFSC) consisting of 58 kcal%
fat (primarily lard) and 28 kcal% carbohydrates (with
17.5 kcal% from sucrose; D09071704, Research Diets
Inc), [33] or a low-fat control diet (LF, 10 kcal% fat;
D12450B; Research Diets Inc.) for up to 20 weeks. Fur-
ther details about composition of the used diets are
presented as Additional file 1: Table S1. In addition,
ApoE−/− mice were fed HFSC for 16 weeks. LDLR−/− mice
on LF served as a negative control for adipose tissue
inflammation and insulin resistance.
All mice were housed in a specific pathogen-free facility
on a 12-hour light/dark cycle with free access to food
and water. Food intake and weight gain were monitored
throughout the studies. To determine food intake, diets
were weighed before and after food change and difference
was calculated as estimated food intake. Blood was drawn
after a 3-hour fasting period immediately before mice were
sacrificed. Gonadal adipose tissue and liver samples were
collected and immediately snap frozen in liquid nitrogen.
The study protocols were approved by the Austrian
Federal Ministry for Science and Research and followed
the guidelines on accommodations and care of animals
formulated by the European Convention for Protection
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Metabolic analyses
Plasma triglyceride and cholesterol concentration was
analyzed using an automated analyzer (Falcor 350, A.
Menarini Diagnostics, Florence, Italy). Enzyme-linked
immunosorbent assay kits were used to determine plasma
insulin (Mercodia AB, Uppsala, Sweden) and osteopontin
levels (R&D Systems, Minneapolis, MN USA). Homeosta-
sis model assessment of insulin resistance (HOMA-IR)
was calculated as an index for insulin resistance [34]. Insu-
lin sensitivity was assessed by insulin tolerance test after a
5-hour fasting period. Briefly, intraperitoneal injection of
recombinant human insulin aspart (Novo Nordisk A/S,
Denmark) at a dose of 0.75 U/kg body weight was given
to HFC- and HFSC-fed LDLR−/− mice and HFSC-fed
ApoE−/− mice. Blood glucose concentrations were de-
termined before and 30, 60, 90 and 120 minutes after
insulin injection. Glucose tolerance test was performed
after a 6-hour fasting period and blood glucose was
measured before and 15, 45, 75, 105 and 135 minutes
after intraperitoneal injection of 20% glucose (0.75 g/kg
body weight).
FPLC analysis of plasma lipoproteins
To analyze plasma lipoproteins 12 μL of EDTA-treated
plasma were injected by autosampler into an Agilent 1200
HPLC instrument equipped with a Superose 6 10/300
gel-filtration FPLC column which separates the intact
lipoproteins by size. An in-line assay for total cholesterol
(Infinity Cholesterol reagent, Thermo Scientific) was per-
formed at 37°C using a post-column reaction. Reaction
products were monitored in real-time at 500 nm and the
data analyzed using Agilent Chemstation software.
Real-time quantitative RT-PCR
Tissue samples were homogenized in TRIzol reagent
(Life Technologies, Carlsbad, CA, USA) and RNA was
isolated according to the manufacturer’s protocol. One
microgram of total RNA was treated with DNase I and
transcribed to cDNA using Superscript II and random
hexamer primers (all Invitrogen) as described [35].
Gene expression of F4/80 (Emr1, Mm00802530_m1),
MCP-1 (Ccl2, Mm00441242_m1), TNFα (Tnf, Mm00443
258_m1), IL-6 (Il6, Mm00446190_m1), osteopontin (Spp1,
Mm00436767_m1), adiponectin (Adipoq, Mm0045642
5_m1), fatty acid synthase (Fasn, Mm00662319_m1),
acetyl-CoA carboxylase (Acaca, Mm01304289_m1), stear-
oyl-CoA desaturase 1 (Scd1, Mm00772290_m1), CD3
(Cd3e, Mm01179194_m1), CD8 (Cd8a, Mm0118210
8_m1), FoxP3 (Foxp3, Mm00475162_m1), CD19 (Cd19,
Mm00515420_m1), fatty acid binding protein 4 (FABP4;
Fabp4, Mm00445878_m1), leptin (Lep, Mm00434759_m1),and peroxisome proliferator-activated receptor γ (PPARγ;
Pparg, Mm01184322_m1) was analyzed by quantitative
real-time RT-PCR on an ABI Prism 7000 cycler using
assays-on-demand kits (TaqMan® Gene Expression Assay,
Life Technologies) and normalized to ubiquitin C mRNA
(Ubc, Mm01198158_m1).
Liver histology and Oil Red-O staining
Liver tissue was embedded in OCT and samples were cut
into 5-μm section, and stained with hematoxylin-eosin.
To further evaluate hepatic lipid content with Oil Red
O cryosections (7 μm) were fixed in 60% isopropanol for
5 min and stained with 0.5% Oil Red-O (Sigma-Aldrich)
in 60% isopropanol for 20 min, and finally counterstained
with hematoxylin. Sections were analyzed with standard
light microscopy, and relative areas of lipid accumulation
(expressed as percentage Oil Red O staining) were quanti-
fied using ImageJ software. A minimum of 5 independent
fields per sample was evaluated.
Atherosclerosis quantification
Atherosclerotic plaque formation was determined using
en face technique as described [36]. Briefly, thorax of
sacrificed mice was opened and aorta was cleaned by
removing fat and connective tissue. Then the aorta was
excised 2 mm above aortic root and below iliac bifur-
cation, opened longitudinally and pinned to silicone plates
with acupuncture needles (asia-med, Suhl, Germany) and
fixed overnight in 4% paraformaldehyde, 5% sucrose,
20 μM EDTA (pH 7.4). Atherosclerotic plaques were
stained with Sudan IV for 15 minutes and destained with
75% ethanol. Pictures were taken with a Sony Z-1000
camera and atherosclerotic lesion area was assessed by a
person blinded to the samples by using ImageJ software.
Statistical analyses
Data are given as means ± SEM. Effects of dietary treat-
ment within LDLR−/− mice were analyzed by one-way
ANOVA using Dunnett’s multiple comparisons test. Com-
parisons between LDLR−/− and ApoE−/− mice both fed
HFSC were assessed by unpaired two-tailed Student t test.
A P value of ≤0.05 was considered statistically significant.
Results
Sucrose-enriched high-fat diet induces earlier insulin
resistance and dyslipidemia
In order to establish an appropriate mouse model for
cardio-metabolic disease, we placed male LDLR−/− mice
either on a low-fat control diet (LF) or two different high-
fat diets, namely a common high-fat diet containing 0.15%
cholesterol (HFC) or a high-fat diet rich in sucrose with
0.15% cholesterol (HFSC). In addition, ApoE−/− mice
which were used as a positive control for atheroscler-
otic plaque formation were fed HFSC. Baseline fasting
Neuhofer et al. Cardiovascular Diabetology 2014, 13:23 Page 4 of 12
http://www.cardiab.com/content/13/1/23glucose and insulin concentration before diet start did
not significantly differ between LDLR−/− and ApoE−/−
mice (Additional file 1: Table S2). LDLR−/− mice fed
both HFSC and HFC developed significant diet-induced
obesity compared to LF-fed controls with no significant
difference between diets (Figure 1A). Also ApoE−/−
mice on HFSC showed marked obesity (Figure 1A).
Gonadal adipose tissue weight was not significantly
altered between HFSC and HFC-fed LDLR−/− mice as
well as LDLR−/− compared to ApoE−/− mice both on
HFSC (Additional file 2: Figure S1).Figure 1 Sucrose-enriched high-fat diet induces earlier insulin resista
or two different high-fat diets both containing 0.15% cholesterol with (HFS
Mean body weight after dietary treatment up to 20 weeks (A). Fasting plasma
diets for 12 weeks (B and C; n = 8 animals per group except LF-fed LDLR−/−
injection of 0.75 g 20% glucose/kg body weight after 12 weeks of feeding (n
and glucose tolerance (G) after dietary treatment for 20 weeks (n = 5–6 a
LF were compared with HFC-fed LDLR−/− mice. In addititon, LDLR−/− and
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.After dietary treatment for 12 weeks fasting plasma
insulin and HOMA-IR in LDLR−/− mice was higher in the
HFSC and HFC group compared to LF. Moreover, HFSC
feeding significantly increased fasting insulin level com-
pared to HFC-fed LDLR−/− mice indicating pronounced
insulin resistance in animals on HFSC (Figure 1B). Corres-
pondingly, HOMA-IR in LDLR−/− mice on HFSC was
significantly increased compared to the HFC-fed group
(Figure 1C). ApoE−/− mice developed significantly less
pronounced insulin resistance than LDLR−/− mice both on
HFSC (Figure 1C). Testing whole body insulin tolerancence in obese LDLR−/− mice. LDLR−/− mice were placed on LF control
C) or without sucrose enrichment (HFC). ApoE−/− mice were fed HFSC.
insulin and HOMA-IR was determined after treatment with indicated
mice with n = 6). Glucose tolerance test was performed by intraperitoneal
= 8 animals per group) (D). Fasting plasma insulin (E), HOMA-IR (F)
nimals per group). For statistical analysis LDLR−/− mice fed HFSC or
ApoE−/− mice both fed HFSC were compared. All data represent
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HFC group (Additional file 2: Figure S1) while glucose
tolerance was impaired in HFSC-fed LDLR−/− mice as
illustrated by significantly increased glucose levels in
response to a glucose tolerance test at the 15-minute
time point (Figure 1D). After 20 weeks on diet, how-
ever, there were no differences in fasting insulin levels,
HOMA-IR and glucose tolerance in LDLR−/− mice on
HFSC and HFC (Figure 1E-G) while body weight did
not increase further.
Compared to LF-fed LDLR−/− mice, both groups on
HFC and HFSC developed hypertriglyceridemia and
hypercholesterolemia (Figure 2A,B). Fasting triglyceride
levels tended to be higher (P = 0.07) and total cholesterol
was significantly elevated in LDLR−/− mice on HFSC
compared to those on HFC (Figure 2A,B).
Fractionation of plasma lipoproteins by FPLC revealed
markedly increased cholesterol in VLDL and LDL frac-
tions of obese LDLR−/− mice on both high-fat diets com-
pared to lean LF-fed LDLR−/− mice after 16 and 20 weeks
of feeding (Figure 3A,B). Lipoprotein profile of HFSC-fed
LDLR−/− mice showed elevated VLDL (P = 0.013) and
LDL (P = 0.04) cholesterol compared to HFC-fed group
after 16 but not 20 weeks of diet (Figure 3A,B). In
addition, cholesterol in the VLDL and LDL fractions was
significantly lower (P ≤ 0.001) in HFSC-fed ApoE−/− mice
than HFSC-fed LDLR−/− mice as shown in Figure 3A.
Sucrose-enrichment of high-fat diet induces more
pronounced adipose tissue and hepatic inflammation
after 16 weeks of feeding
Cytokines secreted by adipose tissue, so-called adipokines,
induce local and systemic low-grade inflammation in
obesity. In obese adipose tissue macrophages represent
the main source of inflammatory adipokines although
other cell types, such as lymphocytes, adipocytes, andFigure 2 Effect of dietary treatment on plasma lipids. Analysis of fastin
animals fed HFSC, HFC or LF and ApoE−/− mice fed HFSC for 16 weeks (n = 5
were compared with HFC-fed LDLR−/− mice. In addititon, LDLR−/− and ApoE−
*P < 0.05; **P < 0.01, ***P < 0.001.pre-adipocytes may contribute. To investigate the dietary
impact on obesity-associated adipose tissue inflammation
in LDLR−/− mice we next analyzed expression of in-
flammatory adipokines and estimated accumulation of
macrophages, T cells and B cells in gonadal adipose tissue.
After dietary treatment for 16 weeks mRNA expression
of Emr1, the gene encoding macrophage marker F4/80,
as well as mRNA levels of the inflammatory genes for
TNFα (Tnf ), IL-6 (Il6), MCP-1 (Ccl2) and osteopontin
(Spp1) were significantly higher in adipose tissue of
obese LDLR−/− mice on both high-fat diets compared
to lean control group on LF (Figure 4). In contrast gene
expression of the anti-inflammatory and insulin-sensitiz-
ing adiponectin (AdipoQ) as well as expression of typical
genes related to adipocyte function such as those for
PPARγ (Pparg), FABP4 (Fabp4) and fatty acid synthase
(FAS, Fasn) was significantly lower in obese LDLR−/− mice
on both high-fat diets compared to LF-fed group after 16
weeks of feeding (Figure 4F and Additional file 3: Figure
S4). Adipose tissue expression of the marker genes specific
for pan-T cells (Cd3e), cytotoxic (Cd8a), and regulatory T
cells (Foxp3) as well as B cells (Cd19) revealed no sig-
nificant obesity-induced alterations after both high-fat
diets compared to lean LF-fed LDLR−/− mice (Additional
file 4: Figure S2). In LDLR−/− mice adipose tissue inflam-
mation was significantly higher than in ApoE−/− mice fed
the same diet (Figure 4).
Notably, after 16 weeks of feeding adipose tissue in-
flammation was more pronounced in LDLR−/− mice on
HFSC than on HFC as indicated by significantly higher
mRNA levels of the genes encoding macrophage marker
F4/80, TNF-α, and osteopontin (Figure 4A,B,E). More-
over, the marked increase of osteopontin mRNA levels in
adipose tissue was accompanied by a borderline significant
increase of osteopontin plasma levels in the HFSC-fed
group only (P = 0.07), while osteopontin plasma levelsg plasma levels of triglycerides (A) and cholesterol (B) in LDLR−/−
animals per group). For statistical analysis LDLR−/− mice fed HFSC or LF
/− mice both fed HFSC were compared. All data represent mean ± SEM.
Figure 3 Analysis of plasma lipoprotein profiles after dietary treatment. Cholesterol lipoprotein distribution after dietary treatment with
indicated diets for 16 weeks (A) and 20 weeks (B) was analyzed using FPLC (n = 5–6 animals per group). All data represent mean.
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(Figure 4G). After 20 weeks of feeding, all mice showed
similar osteopontin plasma levels (Figure 4G).
After 20 weeks on diet, adipose tissue inflammation
remained more pronounced in high-fat diet-fed LDLR−/−
mice compared to LF while adipose tissue inflammation
in the HFSC and HFC group did not remain significantly
different from each other suggesting a delayed peak of
inflammation in the HFC group (Figure 4).
In order to characterize impact of HFSC compared to
HFC feeding on metabolic phenotype in LDLR−/− mice in
more detail, we next determined hepatic lipid accumula-
tion and inflammation after treatment with indicated diets.
LDLR−/− mice on both high fat diets (HFSC or HFC) de-
veloped extensive hepatic steatosis, compared to LF-fed
lean controls after 16 as well as 20 weeks of feeding(Additional file 5: Figure S3). Hepatic lipogenic gene
expression for FAS (Fasn) and acetyl-CoA carboxylase
(ACC; Acaca) but not stearoyl-CoA desaturase 1 (SCD1;
Scd1) were elevated in HFSC- compared to HFC-fed
LDLR−/− mice after 16 weeks of treatment (Figure 5A-C).
In addition, hepatic inflammation was significantly
elevated in obese LDLR−/− mice on both high-fat diets
compared to the LF group as shown by increased mRNA
expression of the genes for macrophage marker F4/80,
MCP-1 and TNFα after 16 weeks of feeding (Figure
5D-F). This high-fat diet-induced increase of hepatic in-
flammation was even more pronounced after 20 weeks
of diet. Of note, HFSC feeding of LDLR−/− mice for 16
weeks induced a significant higher expression of
osteopontin and TNFα compared to HFC-fed animals
(Figure 5F, G). These differences in inflammatory gene
Figure 4 A sucrose-rich high-fat diet for 16 weeks increases adipose tissue inflammation in obese LDLR−/− mice. LDLR−/− mice were fed
HFSC, HFC or LF for 16 or 20 weeks (n = 6 animals per group). ApoE−/− mice were fed HFSC for 16 weeks (n = 8 animals per group). Gonadal
adipose tissue expression of the genes for macrophage marker F4/80 (encoded by Emr1) (A), TNFα (Tnf) (B), IL-6 (Il6) (C), MCP-1 (Ccl2) (D),
osteopontin (OPN; Spp1) (E) and adiponectin (AdipoQ) (F) was analyzed by real-time RT-PCR. Plasma osteopontin was determined by a commercially
available ELISA (G). For statistical analysis LDLR−/− mice fed HFSC or LF were compared with HFC-fed LDLR−/− mice. In addititon, LDLR−/− and ApoE−/−
mice both fed HFSC were compared. All data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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gesting that using a sucrose-enriched high-fat diet ac-
celerates some features of fatty liver inflammation.
Sucrose-enriched high-fat diet accelerates atherosclerotic
lesion development
To next determine if HFSC feeding affects atherosclerosis
development, atherosclerotic lesion area was quantified inthe entire aorta by en face analysis. After 16 weeks of diet-
ary treatment, HFSC-fed LDLR−/− mice achieved similar
levels of atherosclerotic lesion area as HFSC-fed ApoE−/−
mice which we used as a positive control (Figure 6A).
In addition, atherosclerotic lesion formation was signifi-
cantly increased in LDLR−/− mice fed HFSC compared to
LDLR−/− mice fed HFC for 16 weeks (Figure 6A,C). Only
after 20 weeks of dietary treatment, LDLR−/− mice on
Figure 5 Sucrose-enriched high fat diet partly accelerates hepatic inflammation. LDLR−/− mice were fed either HFSC, HFC or LF for 16 or 20
weeks (n = 6 animals per group). ApoE−/− mice were fed HFSC for 16 weeks (n = 8 animals per group). Hepatic lipogenic gene expression of FAS
(Fas) (A), ACC (Acaca) (B), SCD-1 (Scd1) (C) and hepatic expression of the inflammatory genes for macrophage marker F4/80 (encoded by Emr1)
(D), MCP-1 (Ccl2) (E), TNFα (Tnf) (F), and osteopontin (OPN; Spp1) (G) were analyzed by real-time RT-PCR. For statistical analysis LDLR−/− mice fed
HFSC or LF were compared with HFC-fed LDLR−/− mice. In addititon, LDLR−/− and ApoE−/− mice both fed HFSC were compared. All data represent
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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Discussion
Obesity and particularly the metabolic syndrome are
associated with both, type 2 diabetes based on insulin
resistance and cardiovascular disease. Obesity induces
adipose tissue inflammation, which plays a key role in the
development of obesity-driven metabolic complications
leading the way to type 2 diabetes and cardiovasculardiseases [2,5]. Our data show and confirm that both
LDLR−/− and ApoE−/− mice develop diet-induced obesity
on high-fat diets, while LDLR−/− mice are more prone
to adipose tissue inflammation and insulin resistance in
addition to atherosclerosis. Hence, this genetic background
turned out to be more suitable for investigation of cardio-
metabolic disease. Moreover, we show here that using
sucrose rather than more complex carbohydrates in a
high-fat diet significantly accelerated the development
of obesity-induced adipose tissue inflammation, insulin
Figure 6 A sucrose-rich high-fat diet accelerates atherosclerotic plaque formation. LDLR−/− mice were fed HFSC, HFC or LF and ApoE−/−
mice were fed HFSC. Atherosclerotic lesion formation was quantified using en-face analysis after dietary treatment for 16 weeks (A; n = 5 animals
per group) or 20 weeks (B; n = 6 animals per group). C: Representative image of Sudan IV-stained aorta of indicated group after dietary treamtent
for 16 weeks. For statistical analysis LDLR−/− mice fed HFSC or LF were compared with HFC-fed LDLR−/− mice. In addititon, LDLR−/− and ApoE−/−
mice both fed HFSC were compared. All data represent mean ± SEM. *P < 0.05, ***P < 0.001.
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in LDLR−/− mice leading to suitable readouts already after
12 to 16 weeks of dietary treatment.
After dietary treatment of LDLR−/− mice with HFSC or
HFC for 16 weeks mice on HFSC revealed significantly
more pronounced adipose tissue inflammation as shown
by elevated adipose tissue expression of the inflammatory
genes for F4/80, osteopontin and TNF-α Increased gene
expression of F4/80, a typical macrophage marker, indi-
cates macrophage accumulation, while increased osteopon-
tin and TNF-αm RNA levels provide additional evidence
for local inflammation. Strikingly, after four more weeks,
adipose tissue inflammation in LDLR−/− mice fed HFSC
or HFC reached similar levels of inflammatory gene ex-
pression suggesting that the high sucrose uptake speeds
up rather than augments the detrimental effects of high-fat and cholesterol-rich diets. In addition to adipose tissue
inflammation, LDLR−/− mice fed HFSC further demon-
strated increased hepatic inflammation compared to HFC-
fed LDLR−/− mice after 16 weeks of feeding while these
differences evened out after 20 weeks. These results
may indicate an important role of dietary macronutri-
ent composition e.g. on inflammatory alterations which
grossly exceeds its effect on body weight [37-39].
At earlier time points, we observed marked differences
in adipose tissue inflammation, insulin levels, HOMA-IR,
and glucose tolerance between the LDLR−/− animals on
HFSC and those on HFC while the insulin tolerance test
did not show significant differences suggesting that whole
body insulin resistance was not affected by HFSC. Strik-
ingly, after 20 weeks on diet, the stabilization of adipose
tissue inflammation was mirrored by comparable levels of
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might support the notion that adipose tissue inflammation
contributes to insulin resistance [6,40]. On the other hand,
this observation could be due to the fact that after a
certain time span of feeding maximal biological effects
might be reached in HFSC-fed LDLR−/− mice and thus
reach a plateau while HFC-fed LDLR−/− mice then “catch
up” with the HFSC-fed group. In general this might be
an issue of many experimental diets which are often
very extreme in their composition to reach maximum
biological effects very fast. Moreover, although body
weight after dietary treatment of LDLR−/− mice with
HFSC or HFC for 12 weeks did not differ, total body
weight exposure (area under the body weight curve)
was moderately higher in HFSC- compared to HFC-fed
group (LDLR−/− mice on HFSC: 807 ± 23 and HFC:
737 ± 14), which could also contribute to difference in
metabolic parameters at this time point.
Notably, mice on both diets used in this study appeared
healthy at any time point, which is an advantage over
the widely used Western Diets which reportedly leads
to changes in fur and skin integrity even leading to
ulceration or sudden weight loss [41].
After 16 weeks of diet LDLR−/− mice on HFSC but not
on HFC developed atherosclerotic lesion areas comparable
to the commonly used ApoE−/− model. The significant
early increase of total plasma cholesterol as well as an
increase of VLDL and LDL cholesterol levels in HFSC-
fed LDLR−/− mice may certainly contribute to plaque
formation and represent major risk factors for athero-
sclerosis [42]. On the other hand, the marked adipose
tissue inflammation and insulin resistance in HFSC-fed
animals might further suggest an association between
obesity-induced inflammation and atherosclerotic plaque
formation which was described in murine models [43] and
is evident in clinical trials [44,45].
In addition to increased osteopontin mRNA levels in
adipose tissue and liver, plasma osteopontin was in
trend upregulated by the sucrose-enriched high-fat diet
(HFSC; P = 0.077), but not the common high-fat diet
(HFC) confirming earlier results that high-fat diet
locally upregulates osteopontin in tissue but not in
plasma [46]. HFSC-induced elevated plasma osteopontin
could be directly related to its upregulation by glucose,
which was shown in vascular smooth muscle cells and ar-
teries of diabetic patients [47,48]. Thus, osteopontin seems
to primarily act locally and is closely related to athero-
sclerotic disease and cardiovascular events in patients [49].
In humans it is well known that diets with a high dietary
glycemic load lead to inflammation, insulin resistance and
impaired beta-cell function [20,22] and promote weight
gain [50]. Of course one has to bear in mind that mice
used in this study were of C57BL/6 background which is
known to have smaller islet mass and more prominentislet inflammation than other mouse strains, [51] but
C57BL/6 are a widely accepted mouse model for obesity-
associated complications.
Here we show that in LDLR−/− mice addition of sucrose
to a high-fat diet induces earlier and more pronounced
adipose tissue inflammation, insulin resistance, glucose
intolerance and atherosclerosis. As sucrose consists of
both fructose and glucose our findings of worsened
cardio-metabolic situation in LDLR−/− mice fed HFSC
may be due to the high glycemic load on the one hand
and fructose-induced adverse effects on the other hand.
E.g. sucrose could partly contribute to accelerated in-
flammation through fructose, which has been shown to
activate inflammatory pathways such as NF-κB signal-
ing and to induce oxidative stress in animal models
which might further contribute to inflammatory alter-
ations [52-54]. Moreover, fructose in high amounts has
been shown to decrease insulin sensitivity more than
glucose and to induce ectopic and visceral fat depos-
ition, de novo lipogenesis, higher blood pressure and
blood uric acid concentrations [23,55]. The fact that
fructose absorption is enhanced in presence of glucose
[56], may explain why fructose-enriched diets alone could
not induce insulin resistance in LDLR−/− mice [57].
Conclusions
In conclusion, our study demonstrates that feeding
LDLR−/− mice a sucrose-rich high-fat diet (HFSC) con-
stitutes a fast and suitable animal model to investigate
the pathogenesis of cardio-metabolic disease including
adipose tissue inflammation, insulin resistance and ath-
erosclerosis. Saving a couple of weeks in every animal
experiment will provide a significant advantage in every-
day research. In addition, our data point to the close
interrelation between adipose tissue inflammation, insulin
resistance and atherosclerosis.
Additional files
Additional file 1: Table S1. Composition of the used diets. Table S2:
Baseline characteristics.
Additional file 2: Figure S1. LDLR-/- mice were placed on LF control
or two different high-fat diets both containing 0.15% cholesterol with (HFSC)
or without sucrose enrichment (HFC). ApoE-/- mice were fed HFSC. Mean go-
nadal adipose tissue (GWAT) weight after dietary treatment for 16 and 20
weeks (A, B). Insulin tolerance test was performed by intraperitoneal injection
of 0.75 g insulin/kg body weight after 12 and 20 weeks of feeding. Asterisk
indicates significant difference between ApoE-/- and LDLR-/- mice on HFSC
(n = 8 animals per group) (C, D). For statistical analysis LDLR-/- mice fed HFSC
or LF were compared with HFC-fed LDLR-/- mice. In addititon, LDLR-/- and
ApoE-/- mice both fed HFSC were compared. All data represent mean ± SEM.
*P < 0.05, **P< 0.01, ***P< 0.001.
Additional file 3: Figure S4. LDLR-/- mice were fed HFSC, HFC or LF
for 16 or 20 weeks (n = 6 animals per group). ApoE-/- mice were fed
HFSC for 16 weeks (n = 8 animals per group). Gonadal adipose tissue
expression of the genes for PPARγ (Pparg) (A), FABP4 (Fabp4) (B), and fatty
acid synthase (FAS; Fasn) (C), and Leptin (Lep) (D) was determined by
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http://www.cardiab.com/content/13/1/23real-time RT-PCR. For statistical analysis LDLR-/- mice fed HFSC or LF
were compared with HFC-fed LDLR-/- mice. In addititon, LDLR-/- and
ApoE-/- mice both fed HFSC were compared. All data represent mean ±
SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
Additional file 4: Figure S2. LDLR-/- mice were fed HFSC, HFC or LF for
16 or 20 weeks (n = 6 animals per group). ApoE-/- mice were fed HFSC for
16 weeks (n = 8 animals per group). Gonadal adipose tissue expression of
the marker genes for pan-T cells (Cd3e) (A), cytotoxic (Cd8a) (B), and regula-
tory T cells (Foxp3) (C) as well as B cells (Cd19) (D) was analyzed by real-time
RT-PCR. For statistical analysis LDLR-/- mice fed HFSC or LF were compared
with HFC-fed LDLR-/- mice. In addititon, LDLR-/- and ApoE-/- mice both fed
HFSC were compared. All data represent mean ± SEM.
Additional file 5: Figure S3. LDLR-/- mice were fed either HFSC, HFC
or LF for 16 or 20 weeks and ApoE-/- mice were fed HFSC for 16 weeks.
Hematoxylin-esoin and Oil Red O staining of liver sections was performed
(n = 4-5 animals per group). Representative pictures after dietary
treatment for 16 (A) or 20 weeks (B) are given in 20-fold magnification.
Quantification of lipid accumulation in Oil Red O-stained sections (C). For
statistical analysis LDLR-/- mice fed HFSC or LF were compared with HFC-
fed LDLR-/- mice. In addititon, LDLR-/- and ApoE-/- mice both fed HFSC
were compared. All data represent mean ± SEM.
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